Predicting tumor response to anti-ERBB3 antibodies

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9828635
SERIAL NO

14349916

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
AVEO PHARMACEUTICALS INC30 WINTER STREET BOSTON MA 02108

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bottega, Steve Cambridge, US 10 43
Feng, Bin Newton, US 166 987
Gyuris, Jeno Lincoln, US 63 604
McIntosh, Donna Chelmsford, US 3 15
Meetze, Kristan Lexington, US 22 178
Nicoletti, Richard Southborough, US 6 45
Tyler, Steven Boston, US 23 672
Vincent, Sylvie Somerville, US 10 85

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 28, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 28, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00